Table 4 Percent of heteroplasmy calls out of total number of sequence variants.
From: Performance of mitochondrial DNA mutations detecting early stage cancer
Genomes sequenced | Number of sequence variants | Number (%) of heteroplsmy sequence variants | Number (%) of specimens with heteroplasmy |
|---|---|---|---|
Blood from patients with cancer – 26 | 391 | 27 (6.9%)* | 18 (69.2%)* |
Tumor – 24 | 411 | 43 (10.5%)* | 18 (75.0%)* |
BF from patients with cancer – 22 | 293 | 11 (3.8%) | 7 (31.8%) |
Blood from individuals without cancer -12 | 202 | 7 (3.5%) | 4 (33.3%) |
Sputum from individuals without cancer – 12 | 206 | 11 (5.3%) | 5 (41.7%) |